Consistent with other reports, apigenin has been demonstrated to be an effective agent for inhibiting cell migration in CD44+ prostate cancer cells [42] and colorectal cancer cells (DLD1 and SW480) [43]. This evidence concerns the gene CD44 and prostate carcinoma.